The Human Milk Oligosaccharides Market, estimated at USD 342.5 Mn in 2025, is expected to exhibit a CAGR of 14.7% and reach USD 895.2 Mn by 2032.
The Food and Beverages sector is driving global growth, balancing rising consumer demand for sustainable, healthier options with industry investments in digital transformation, e-commerce, and supply chain innovation.
Increasing imports of HMOs
As domestic production of human milk oligosaccharides is currently limited, companies are increasingly importing HMOs extracted from cow's milk or produced recombinantly through fermentation of microorganisms. This is driving the global supply of HMOs and facilitating their inclusion in infant formula and other products.
Developments in extraction techniques
Traditionally, HMOs were extracted from donated human milk which was an unscalable process. However, recent scientific advances have enabled the extraction of HMOs from cow's milk or their production through fermentation methods. This has significantly improved yields and made largescale production commercially viable. Several companies have also developed proprietary cost-effective extraction technologies which is supporting the expansion of the human milk oligosaccharides market.
Increasing Awareness about the Health Benefits of HMOs is Driving the Market Growth
One of the major drivers for the growth of the human milk oligosaccharides market is the increasing awareness among consumers about the various health benefits offered by HMOs. Research has shown that HMOs act as prebiotics and help in the growth of beneficial bacteria in the gut of infants. This helps in supporting the immune system development and reducing the risks of gastrointestinal infections. HMOs have also been found to help prevent conditions like necrotizing enterocolitis which is a serious disease that affects premature infants. As more people come to know about these proven health advantages, the demand for HMO-enriched infant formula and supplements is growing steadily. Manufacturers are leveraging this driver by highlighting the clinical research backing HMOs and their role in infant and digestive health.
Growing Demand for Alternative Feeding Options is Boosting Market Adoption
Another key growth driver is the rising demand for alternative feeding options among working mothers and families where breastfeeding is not possible. With more women joining the workforce globally, the demand for breastmilk substitutes that can provide similar nutritional composition and balance is on the rise. Since HMOs are the third largest solid component found in breastmilk after fat and lactose, adding them to formula makes the products more comparable to human milk. The lack of direct breastfeeding also increases the need for supplementation of prebiotic HMOs through formula, baby food, and supplements. Manufacturers are leveraging this driver by positioning their HMO products as close alternatives to breastmilk for supplementation as well as sole nutrition in non-breastfed infants.
High Production Costs Pose Constraint on Commercialization
One of the major restraints hampering the growth potential of this market is the high production costs associated with manufacturing HMOs at commercial and industrial scales. human milk oligosaccharides are complex sugar structures that are currently extracted from breast milk in limited quantities via expensive methods. Alternative production methodologies like chemical synthesis and microbial fermentation are still under development phases and have low yields. The costs of extraction, purification and production strain the profit margins for manufacturers. Unless production processes become more refined and cost-efficient on a bulk scale, high costs may limit widespread adoption and commercial availability of HMO products. This is a challenge that producers are trying to overcome through process innovation and investment in large-scale production facilities.